Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP8B1 | Q9UNU6 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965991 | 1.00 | P2RY12 (0.59) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1966315 | 1.00 | P2RY12 (0.59) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1966326 | 0.96 | P2RY12 (0.59) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1966329 | 0.96 | P2RY12 (0.59) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1967887 | 0.96 | P2RY12 (0.58) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1967885 | 0.96 | P2RY12 (0.58) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1971721 | 0.96 | P2RY12 (0.58) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1967180 | 0.96 | P2RY12 (0.58) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1967181 | 0.96 | P2RY12 (0.58) | P2RY12DPP4MTNR1AMTNR1BMEN1 | |
| SCHEMBL1972836 | 0.96 | P2RY12 (0.61) | P2RY12DPP4MEN1KMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | P2RY12 127/4885DPP4 1926/4885MTNR1A 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.